Production (Stage)
ImmunityBio, Inc.
IBRX
$3.44
$0.299.21%
NASDAQ
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Net Income | 3.33% | 74.65% | 10.31% | 2.40% | -15.27% |
Total Depreciation and Amortization | -15.94% | -9.33% | -2.84% | -5.89% | -2.69% |
Total Amortization of Deferred Charges | -- | -29.66% | -45.88% | -52.54% | -51.90% |
Total Other Non-Cash Items | 196.17% | -118.37% | -1,491.37% | -41.96% | 276.45% |
Change in Net Operating Assets | -466.02% | 57.89% | -43.51% | -40.80% | -114.07% |
Cash from Operations | 19.70% | 26.14% | -13.00% | -25.79% | -26.89% |
Capital Expenditure | 11.10% | 73.46% | 50.80% | 91.51% | 85.04% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | 115.28% | 17.06% | 781.24% | -64,984.62% | -61,258.93% |
Cash from Investing | 111.59% | 337.26% | 516.05% | -498.44% | -319.87% |
Total Debt Issued | -- | -100.00% | -51.28% | -- | -- |
Total Debt Repaid | -- | 100.00% | -15.79% | -10.53% | -10.53% |
Issuance of Common Stock | -98.44% | 1,051.35% | -60.23% | 284.52% | -70.23% |
Repurchase of Common Stock | 68.92% | 48.59% | 79.58% | -726.67% | -983.19% |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | -- | -- |
Cash from Financing | -109.60% | -46.68% | -93.44% | 242.98% | -86.70% |
Foreign Exchange rate Adjustments | 74.36% | 74.07% | 1,200.00% | 220.00% | 84.65% |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | 37.49% | -63.87% | -113.49% | 93.48% | -719.42% |